Poly Medicure Limited · NSE:POLYMED
Poly Medicure — Shareholder Meeting (September 2023)
31 slides from Poly Medicure's shareholder meeting presentation, September 2023
Slide 1: Welcome to 28th Annual General Meeting
Welcome to 28 th Annual General Meeting September 2023 Poly Medicure Limited Infusion Therapy & Vascular Access Dialysis & Renal Care Transfusion System Diagnostics Oncology Critical Care Confidential I Slide 1 www.polymedicure.com
Slide 2: Disclaimer
DISCLAIMER This presentation has been prepared by Poly Medicure Limited (the “Company”) solely for your information and may not be distributed, reproduced, or redistributed or passed on directly or indirectly to any other person, whether within or outside your organization or firm, or published in wh
Slide 3: Table Of Content
Table Of Content Polymed at a Glance 4 Manufacturing Excellence 14 A sucess story spanning 5 Capex Update 15 Corporate Structure 6 Research and Development 18 Board of Directors 7 Proposed New Products 20 India Business Leadership Team 8 Euporean Polymed Strategy 21 Financial Snapshot & Strength 9 P
Slide 4: Polymed at a Glance
Polymed at a Glance 125+ 160+ 3000+ Countries Medical Devices Employee Base 350+ 30+ Sales Associates Clinical Specialists INR 1115 1 Billion+ Crores Devices Manufacturing Capacity per year Consolidated Revenue Largest Reach in Exporter 8,000+ of consumable Medical Hospitals in India devices for 10
Slide 5: A Success Story spanning over 26 Years
A Success Story spanning over 26 Years 2003 Joint Venture in Assuit, Egypt 2011 Company listed in National Stock 2018 Exchange Forayed in Renal Care (Dialysis) PolyHealth 2004 Medical Inc. Faridabad (US subsidiary of 2021 Plant 2 Poly Medicure Ltd.) 2009 2016 China Plant New R&D 1997 -Poly Medicure
Slide 6: Corporate Structure
Corporate Structure POLYMED GROUP INDIA OVERSEAS Poly Medicure Poly Medicure BV- Ultra for Medical Poly Medicure Ltd (Laiyang) Co. Ltd. China Netherlands Products Co. Subsidiary Subsidiary (UMIC) – Egypt Associate Plan 1 Health India Pvt. Ltd. Plan 1 Health Italy PolyHealth Medical Inc. USA Subsidia
Slide 7: Board of Directors & Management
Board of Directors & Management Mr. Himanshu Baid Mr. Devendra Raj Mehta Mr. Rishi Baid (Managing Director) (Chairman, Non-Execu�ve (Joint Managing Director) Independent Director) Dr. Shailendra Raj Mehta Mr. Jugal Kishore Baid Mrs. Mukulika Baid (Non-Execu�ve) (Non-Execu�ve Director) (Non Execu�ve
Slide 8: Leadership Team
Leadership Team Vishal Baid Naresh Vijay CFO & President, President-Finance Corporate Business Manish Sardana P K Gupta President, President, Operations India Business Hemant Bhalla Rajesh Kumar Sr. Vice President, Vice President, Renal Care Operations Sujit Gupta SS Rawat Associate Vice President,
Slide 9: Our Strength: Consistent all-round growth
Our Strength: Consistent all-round growth (Consolidated) REVENUE (₹ Crores) EBIDTA (₹ Crores) PBT (₹ Crores) PAT (₹ Crores) 1115.23 923.06 269.38 237.49 786.20 195.24 179.28 214.34 213.10 180.04 135.84 146.51 FY 2021 FY 2022 FY 2023 Year Revenue CAGR Year EBIDTA % Year PBT % Year PAT % FY 2021 786.2
Slide 10: Ratio's
Ratio’s Interest Coverage Debt Service Coverage 64.53 9.91 41.34 6.87 5.55 29.58 % % FY 2021 FY 2022 FY 2023 FY 2021 FY 2022 FY 2023 ROCE 16.47% 15.49% 14.05% % FY 2021 FY 2022 FY 2023 Increase in Share Capital due to QIP in Feb 2021 Confidential I Slide 10 www.polymedicure.com
Slide 11: Shareholding Pattern 30 June, 2023
Shareholding Pattern 30 June, 2023 th OTH Promoters and 53.31 % 13% Promoters Group BC Mutual Funds 3.27 % 15% 30thJune, FPIs 15.61 % 2023 P & PG 53% Bodies Corporate 14.94 % FPI 16% Others 12.87 % MF 3% Grand total 100 % Confidential I Slide 11 www.polymedicure.com
Slide 12: Revenue by Region
Revenue by Region TOUCHING MILLIONS OF LIVES EVERYDAY ACROSS 125+COUNTRIES Region wise Revenue % Region FY 21-22 FY 22-23 India 34 % 32 % Europe 31 % 35 % India International Rest of World 32% 68% 35 % 33 % Confidential I Slide 12 www.polymedicure.com
Slide 13: Production Linked Incentive
Production Linked Incentive Scheme-I • Polymed got approval under Renal Care Segment • Committed Investment of 70 Crs under the scheme from FY 2022-28 • 25.5 Crs of Investment done upto Mar-23 under the scheme Scheme-II • Polymed got approval under In Vitro Diagnostic Medical devices. New range of M
Slide 14: Manufacturing
Manufacturing (INDIA, ITALY, EGYPT, CHINA) 1st Medical Device Company from India to have overseas plants. Faridabad Plant, India Jaipur Plant, India Laiyang-qingdao, China Over 300+ Moulding Machines & 1200+ Injection Molds Faridabad Plant, India IMT Faridabad India Amaro, Italy More than 200+ autom
Slide 15: Manufacturing-Capex Update
Manufacturing-Capex Update Capex incurred in FY 2022-23 : INR 237 Crores Faridabad Manufacturing and Warehouse Jaipur SEZ Phase - II Commenced Operation in Q1 -2023-24 56A Commenced Operation in Q1 -2023-24 Capex planned for FY 2023-24 : INR 200 Crores *Faridabad Plant 117 *Faridabad IMT Plant II Sc
Slide 16: Manufacturing Excellence
Manufacturing Excellence Confidential I Slide 16 www.polymedicure.com
Slide 17: Manufacturing Excellence
Manufacturing Excellence Confidential I Slide 17 www.polymedicure.com
Slide 18: Research and Development Capabilities
Research and Development Capabilities Development of: • Product Design • Process Design • Mold & Machine Design Patents Granted Pending Patent Applications (as on 31.03.2023) (as on 31.03.2023) Confidential I Slide 18 372 71 www.polymedicure.com
Slide 19: Research and Development Capabilities
Research and Development Capabilities Manufacturing Process • Cannula manufacturing • Ultrasonic Welding • Radio Frequency Welding • Thermal Bonding • Hot Air Welding • Laser Welding • Plasma Welding • UV Gluing & Curing • Hydrophilic Coating • Micro-drilling-Eyelet cut/punch (SS/Plastic) Manufactur
Slide 20: Proposed New Products - FY 23-24
Proposed New Products - FY 23-24 Diagnos�c Catheters Lab side Filter Bed side Filter Ni�nol Guidewires PTCA Balloon Feeding Tube Catheters with Guidewires Plas�c Mini ports Arterial Catheters Centesis Catheters Confidential I Slide 20 www.polymedicure.com
Slide 21: European Polymed Strategy 2023-24
European Polymed Strategy 2023-24 MORE VISIBILITY TO POLYMED BRAND: Headline ROAD FROM B2B TO B2C Italy: tenders/direct business with more Polymed branded devices. Germany/Austria/Swiss: expanding Polymed branded devices. Expand France/Spain: new direct approach to market for products Customer Sales
Slide 22: Plan1 Health Performance
Plan1 Health Performance Revenue Un�l Aug '23 5000 +73% vs PY 4000 § Growth +73% vs. PY un�l Aug.’23 3000 § High Growth for PICCs and MIDs and PORTs REV 2000 4519k€ PY 1000 2606k€ Nearly 4 �mes growth Growth since Polymed acquisi�on 0 CY 2023 PY 2022 Rev vs. Bdg Covid19 Confidential I Slide 22 www.po
Slide 23: North America Business Updates
North America Business Updates Received FDA 510(K) approvals on 3 major products. Submitted 2 more FDA submissions in June of 2023 and we should receive approvals Q1 of FY 25. First order will be shipped out in Q3 of FY24 More products under discussion with new customers. Once finalized will apply fo
Slide 24: India Medical Devices Sector - Overview
India Medical Devices Sector - Overview • Medical devices is a sunrise sector of the Indian economy. • The size of the Indian medical devices market is estimated at USD 11 Billion in 2020, expected to grow to USD 50 Billion by 2030 with CAGR of 16.4%. • The Indian medical device market share in the
Slide 25: Growth Factors: Indian Medical Devices Industry
Growth Factors: Indian Medical Devices Industry • Increase in demand due to increased investments in healthcare infrastructure • Make in India push through PLI & Medical Devices parks • All devices being regulated by CDSCO by 1st Oct 2023 • New R&D policy for medical devices • Dedicated Medical Devi
Slide 26: New National Medical Devices Policy 2023
New National Medical Devices Policy 2023 Vision: • Accelerated growth path with a patient-centric approach • To emerge as the global leader in the manufacturing and innovation of medical devices by achieving 10-12% share in the expanding global market over the next 25 years. • Policy is expected to
Slide 27: New National Medical Devices Policy 2023
New National Medical Devices Policy 2023 Strategies to Promote Medical Device Sector: • Regulatory Streamlining: creation of a Single Window Clearance System, enhancing the Role of BIS and designing a coherent pricing regulation. • Enabling Infrastructure: The establishment and strengthening of larg
Slide 28: Focus on Sustainability
Focus on Sustainability Focus on Predictive & Increase use of Preventive maintenance recycled materials in to reduce down time of packaging machines Utilizing Automation Increase usage of Bio- Tools, AI, IOT & Cobots degradable plastics Mission to to improve safety Reduce Carbon footprint by 30% by
Slide 29: Sustainability Reporting - Our Efforts
Sustainability Reporting - Our Efforts Water Consumption 14.5% Water Saving 18,690 KL Water Recycling by replacing DG set cooling towers with Close loop coil coolers Water reused in Gardening 65,544 KL/Year By reusing water in process system- Chillers, DG Sets, Cooling Towers, Steam Boilers, wash Ro
Slide 30: Awards & Recognition
Awards & Recognition “Top 50 Innovative Companies “Fortune India the next 500 ASSOCHAM, Best Company Award 2022” by Confederation Companies 2023”- Received for Technology Innovation in of Indian Industry – Received in in July 2023 Healthcare, Aug 2023 December 2022 Confidential I Slide 30 www.polymed
Slide 31: Thank You!
Poly Medicure Limited Registered Office: Thank You! 232 B, 3rd Floor, Okhla Industrial Estate, Phase III, New Delhi-110020, India Tel:- 91-11-33550700, 47317000, 26321838/99 For any general queries, Reach us at: info@polymedicure.com Visit: www.polymedicure.com Confidential I Slide 31 www.polymedicure